Facing the challenge of viral mutations in the age of pandemic: Developing highly potent, broad‐spectrum, and safe COVID‐19 vaccines and therapeutics-Reference-Cited by-同舟云学术

Facing the challenge of viral mutations in the age of pandemic: Developing highly potent, broad‐spectrum, and safe COVID‐19 vaccines and therapeutics

Published:2021-01 Issue:1 Volume:11 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical and Translational Medicine

Author:

Su Shan¹,Wang Qian¹,Jiang Shibo¹^ORCID

Affiliation:

1. Key Laboratory of Medical Molecular Virology (MOE/MOH/CAM), School of Basic Medical Sciences Shanghai Institute of Infectious Disease and Biosecurity Fudan University Shanghai China

Publisher

Wiley

Subject

Molecular Medicine,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ctm2.284

Reference20 articles.

1. RambautA LomanN PybusO et al.Preliminary Genomic Characterisation of an Emergent SARS‐CoV‐2 Lineage in the UK Defined by a Novel Set of Spike Mutations.2020https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563. Accessed December 21 2020.

2. KupferschmidtK.Mutant Coronavirus in the United Kingdom Sets Off Alarms But Its Importance Remains Unclear.2020.https://www.sciencemag.org/news/2020/12/mutant-coronavirus-united-kingdom-sets-alarms-its-importance-remains-unclear. Accessed December 20 2020.

3. Adaptation of SARS‐CoV‐2 in BALB/c mice for testing vaccine efficacy;Gu H;Science,2020

4. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

5. Persistence and evolution of SARS‐CoV‐2 in an immunocompromised host;Choi B;N Engl J Med,2020

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The use of RNA-based treatments in the field of cancer immunotherapy;Molecular Cancer;2023-07-07

2. Establishment of national standard for anti-SARS-Cov-2 neutralizing antibody in China: The first National Standard calibration traceability to the WHO International Standard;Frontiers in Immunology;2023-02-14

3. Small molecules in the treatment of COVID-19;Signal Transduction and Targeted Therapy;2022-12-05

4. In silico evaluation of the inhibitory potential of nucleocapsid inhibitors of SARS-CoV-2: a binding and energetic perspective;Journal of Biomolecular Structure and Dynamics;2022-11-15

5. A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life;Viruses;2022-03-22